Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 9, 2020
November 9, 2020
0a6a0a53-093e-48c0-a832-4e3db4e95cd6
Related Documents
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
Guidance DocumentDecember 2, 2019Center for Drug Evaluation and Research
Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry
Guidance DocumentJuly 31, 2023Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022
Guidance DocumentMay 1, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox